Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?

AbbVie is strategically expanding its oncology franchise, which accounted for over 12% of Q1 2025 revenues, by diversifying beyond initial blood cancer drugs like Imbruvica. New additions such as Epkinly, Elahere, and the recently approved, internally developed lung cancer therapy Emrelis are helping offset declining Imbruvica sales, complemented by a robust pipeline including late-stage candidates etentamig and Temab-A. While ABBV shares have outperformed year-to-date with rising earnings estimates, the company operates in a highly competitive oncology market alongside major players like AstraZeneca, Merck, and Pfizer, and its valuation is currently above its five-year average.

Analysis

AbbVie is successfully executing a strategic expansion of its oncology franchise, which constituted over 12% of total revenue in Q1 2025. The company is diversifying from its established blood cancer drugs through a combination of acquisitions (Epkinly, Elahere) and internal development, marked by the recent approval of its first internally developed solid tumor therapy, Emrelis. These new products, along with rising sales from Venclexta, are proving effective in offsetting the revenue decline from Imbruvica, which is under pressure from novel oral therapies. The forward-looking growth narrative is supported by a robust late-stage pipeline, including etentamig for multiple myeloma and Temab-A for colorectal cancer. However, this growth occurs within a highly competitive environment dominated by AstraZeneca, Merck, and Pfizer, whose oncology franchises represent significantly larger portions of their respective revenues at 41%, 46%, and 27%. While AbbVie's stock has outperformed its industry year-to-date, its valuation reflects this optimism; its forward P/E of 13.99x trades above its five-year average of 12.43x, though this is supported by recent upward revisions to 2025 and 2026 earnings estimates to $12.28 and $14.06 per share, respectively.

Key Decisions for Investors

• Investors should monitor the initial sales trajectory of the newly launched lung cancer drug Emrelis starting in Q3 2025, as its performance is a key test of AbbVie's internal R&D capabilities in the solid tumor market.
• Closely track clinical trial readouts and regulatory updates for late-stage pipeline assets etentamig and Temab-A, as positive developments are critical to justifying the company's valuation and sustaining long-term growth.
• Given the stock's valuation is above its five-year average and competition from oncology heavyweights remains intense, consider the current price a reflection of successful strategy execution, with further upside heavily dependent on pipeline success and continued commercial outperformance.